Neurogene Inc.

NGNE

US64135M1053

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 11:35:07 2024-04-25 am EDT			5-day change	1st Jan Change
29.16 ^USD	-3.56%		-6.11%	+52.99%

Mar. 22	North American Morning Briefing : Stocks Struggle After New Records	DJ
Mar. 21	William Blair Initiates Neurogene With Outperform Rating	MT

Neoleukin Therapeutics, Inc.(NasdaqGM:NLTX) dropped from S&P Biotechnology Select Industry Index

September 20, 2021 at 12:00 am EDT

Latest news about Neurogene Inc.

North American Morning Briefing : Stocks Struggle After New Records	Mar. 22	DJ
William Blair Initiates Neurogene With Outperform Rating	Mar. 21	MT
Neurogene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18	CI
North American Morning Briefing : Inflation -2-	Mar. 15	DJ
Neurogene Inc. Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial	Mar. 04	CI
Neurogene Inc. Appoints Donna Cochener as Senior Vice President, General Counsel	Feb. 21	CI
Neurogene Inc. Appoints Julie Jordan as Chief Medical Officer	Jan. 17	CI
Neurogene Names Julie Jordan as Chief Medical Officer	Jan. 16	MT
Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer	Jan. 16	CI
HC Wainwright Starts Neurogene With Buy Rating, $45 Price Target	Jan. 08	MT
Stifel Starts Coverage on Neurogene with Buy Rating, $31 Price Target	Jan. 05	MT
Neurogene Announces Business Update and 2024 Outlook	Jan. 05	CI
Neurogene Completes Merger With Neoleukin Therapeutics	Dec. 19	MT
Neoleukin Therapeutics, Inc.(NasdaqCM:NLTX) dropped from NASDAQ Composite Index	Dec. 18	CI
Neurogene Inc. announced that it has received $95 million in funding from a group of investors	Dec. 17	CI
Neurogene Inc. completed the acquisition of Neoleukin Therapeutics, Inc. from a group of shareholders for approximately $120 million in a reverse merger transaction.	Dec. 17	CI
Neoleukin Therapeutics Board Approves Reverse Stock Split, Increase in Authorized Common Stock Capital to 500 Million	Dec. 15	MT
Neoleukin Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Sector Update: Health Care Stocks Rise Slightly Late Afternoon	23-09-22	MT
Sector Update: Health Care Stocks Mixed Friday Afternoon	23-09-22	MT
Neoleukin Therapeutics Board Approves 1-for-5 Reverse Stock Split	23-09-22	MT
Neoleukin Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Transcript : Neoleukin Therapeutics, Inc., Neurogene Inc. - M&A Call	23-07-18
Neoleukin Therapeutics to Merge With Neurogene in All-Stock Deal	23-07-18	MT
Neurogene Inc. entered into a definitive merger agreement to acquire Neoleukin Therapeutics, Inc. in a reverse merger transaction.	23-07-17	CI

Neurogene Inc. is a clinical-stage biotechnology company. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is under development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in pediatric female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. It is also developing NGN-101 for the treatment of CLN5 Batten disease.

Sector

Biotechnology & Medical Research

Calendar

2024-05-09 - American Society of Gene & Cell Therapy Meeting - Poster No. 1408

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

30.23 USD

Average target price

53.33 USD

Spread / Average Target

+76.43%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NEUROGENE INC.	+52.99%	389M
IQVIA HOLDINGS INC.	+0.75%	43.84B
MODERNA, INC.	+4.64%	41.68B
LONZA GROUP AG	+45.43%	41.25B
CELLTRION, INC.	-11.96%	27.04B
ICON PUBLIC LIMITED COMPANY	+5.56%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-25.35%	18.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.96%	12.29B
MEDPACE HOLDINGS, INC.	+25.30%	12.29B
UNITED THERAPEUTICS CORPORATION	+7.21%	11.15B

Other Biotechnology & Medical Research

Neurogene Inc.

Equities

NGNE

US64135M1053

Biotechnology & Medical Research

Neoleukin Therapeutics, Inc.(NasdaqGM:NLTX) dropped from S&P Biotechnology Select Industry Index

Latest news about Neurogene Inc.

Chart Neurogene Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research